242 related articles for article (PubMed ID: 30611225)
1. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Prognostic Markers {CEA, Ca19.9, Neutrophil To Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)} With Progression Free Survival (PFS) in Advanced/Metastatic Gallbladder Carcinoma.
Naik MD; Kataria SP; Kumar G; Singh R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443542
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma.
Liu F; Hu HJ; Ma WJ; Yang Q; Wang JK; Li FY
Medicine (Baltimore); 2019 Feb; 98(8):e14550. PubMed ID: 30813165
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
5. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer.
Hirooka Y; Ishikawa T; Kawashima H; Ohno E; Nonogaki K; Kanamori A; Hirai T; Uchida H; Shirai O; Ishikawa H; Goto H
Cancer Chemother Pharmacol; 2017 Jul; 80(1):119-125. PubMed ID: 28536803
[TBL] [Abstract][Full Text] [Related]
7. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
8. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
10. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
Sharma A; Kalyan Mohanti B; Pal Chaudhary S; Sreenivas V; Kumar Sahoo R; Kumar Shukla N; Thulkar S; Pal S; Deo SV; Pathy S; Ranjan Dash N; Kumar S; Bhatnagar S; Kumar R; Mishra S; Sahni P; Iyer VK; Raina V
Eur J Cancer; 2019 Dec; 123():162-170. PubMed ID: 31707181
[TBL] [Abstract][Full Text] [Related]
11. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer.
Chatni SS; Sainani RS; Mehta SA; Mohandas KM
J Cancer Res Ther; 2008; 4(4):151-5. PubMed ID: 19052386
[TBL] [Abstract][Full Text] [Related]
12. Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy.
Lee JW; Kim YT; Lee SH; Son JH; Kang JW; Ryu JK; Jang DK; Paik WH; Lee BS
Gut Liver; 2018 Jan; 12(1):102-110. PubMed ID: 29069888
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
Ostwal V; Swami R; Patkar S; Majumdar S; Goel M; Mehta S; Engineer R; Mandavkar S; Kumar S; Ramaswamy A
Med Oncol; 2018 Mar; 35(4):57. PubMed ID: 29564657
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
Ramaswamy A; Ostwal V; Pinninti R; Kannan S; Bhargava P; Nashikkar C; Mirani J; Banavali S
J Hepatobiliary Pancreat Sci; 2017 May; 24(5):262-267. PubMed ID: 28196310
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
Doval DC; Sekhon JS; Gupta SK; Fuloria J; Shukla VK; Gupta S; Awasthy BS
Br J Cancer; 2004 Apr; 90(8):1516-20. PubMed ID: 15083178
[TBL] [Abstract][Full Text] [Related]
17. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma.
Zhang L; Wang R; Chen W; Xu X; Dong S; Fan H; Liu C
HPB (Oxford); 2016 Jul; 18(7):600-7. PubMed ID: 27346141
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Malik IA; Aziz Z; Zaidi SH; Sethuraman G
Am J Clin Oncol; 2003 Apr; 26(2):174-7. PubMed ID: 12714891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
